Low oxygen linked to cancer-related mutations in human kidney cells
A distinctive mutation pattern marked 96% of analyzed clear cell kidney cancers.A distinctive mutation pattern marked 96% of analyzed clear cell kidney cancers.
There are 79 papers on renal cell carcinoma in aging research: 2 trials and 51 observational studies in people, 5 in animals, 2 in cells, 17 reviews. The newest story, Nov 2, 2026: “Low oxygen linked to cancer-related mutations in human kidney cells”.
79 papers study it46 more mention it16 findings
7 new papers in 30 daysSee all 125 papers on renal cell carcinoma
“ANGPTL3 inhibition was also associated with an increased risk of renal cell carcinoma (OR =1.975; 95% CI: 1.217-3.205)”
TMEM72
downin human cells1
TMEM72 protects against renal cell carcinoma in human cells (overexpression).
Cellsoverexpression
Telomere length
upin humans2upin silico1OR 1.96–2.07
Telomere length is linked with a higher risk of renal cell carcinoma in humans (OR 2.07, 95% CI 1.70-2.53).
Humans
Telomere length raises the risk of renal cell carcinoma in silico (OR = 1.96, 95% CI 1.52-2.52).
In silico
Telomere length is associated with renal cell carcinoma in humans (polygenic score using common variants).
Reviewpolygenic score using common variants
BAP1
upin humans1
BAP1 is associated with renal cell carcinoma in humans (RR at 80 years 29.9 (95% CI 3.7–50.8); cumulative risk 49.4%).
HumansHeterozygous germline BAP1 (likely) pathogenic variants; compared with population incidencen = 90
Vegetable intake
downin humans1
Vegetable intake is associated with renal cell carcinoma in humans.
Review
Smoking
upin humans1
Smoking is associated with renal cell carcinoma in humans (ever smoking).
Reviewever smoking
Obesity
upin humans1
Obesity is associated with renal cell carcinoma in humans.
Review
ANGPTL3
upin humans1OR 1.975
ANGPTL3 is linked with a higher risk of renal cell carcinoma in humans (genetically proxied inhibition, drug-target Mendelian randomization) (OR 1.975 (95% CI 1.217-3.205)).
Humansgenetically proxied inhibition, drug-target Mendelian randomization
SGLT2 inhibitors
downin humans1HR 0.85
SGLT2 inhibitors are linked with a lower risk of renal cell carcinoma in humans (type 2 diabetes) (HR 0.85, 95% CI 0.79-0.92).
Humanstype 2 diabetesmean follow-up of 44.2 months
eXtreme Gradient Boosting prediction model
upin humans1
eXtreme Gradient Boosting prediction model predicts renal cell carcinoma in humans (validation cohort) (AUC 0.955 (95% CI: 0.938-0.976); average precision 0.923).
Humansvalidation cohort
Cellular senescence
upin reviews1
Cellular senescence is associated with renal cell carcinoma.
Review
Metabolically unhealthy obesity
upin humans1HR 2.14
Metabolically unhealthy obesity is linked with a higher risk of renal cell carcinoma in humans (compared to MHNO) (HR 2.14, 95% CI 1.969-2.325).
Humanscompared to MHNO
Company14 trialsPhase 45,738 people
Company13 trialsPhase 45,197 people
Novartis Pharmaceuticals Corporation
Company8 trialsPhase 42,593 people
Company21 trialsPhase 310,991 people
Company15 trialsPhase 33,773 people
Company7 trialsPhase 39,186 people
Company7 trialsPhase 32,791 people
Company4 trialsPhase 3749 people
National Cancer Institute$1.7MNational Institute of Arthritis and Musculoskeletal and Skin Diseases$576KUS Department of Veterans Affairs
Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma
National Cancer InstituteBeth Israel Deaconess Medical Center$425K2021–2026
Utilization of Fasting Mimicking Diets to Treat and Prevent Clear Cell Renal Cell Carcinoma
National Cancer InstituteUniversity of Notre Dame$47.7K2022–2024
National Institute of Arthritis and Musculoskeletal and Skin DiseasesJohns Hopkins University$371K2018–2023
Novel Diagnostic Tests for Renal Cell Carcinoma
US Department of Veterans AffairsVeterans Health Administration2016–2021
A distinctive mutation pattern marked 96% of analyzed clear cell kidney cancers.A distinctive mutation pattern marked 96% of analyzed clear cell kidney cancers.